Literature DB >> 11428729

Kernicterus in full-term infants--United States, 1994-1998.

.   

Abstract

Kernicterus is a preventable life-long neurologic syndrome caused by severe and untreated hyperbilirubinemia during the neonatal period. High levels of bilirubin are toxic to the developing newborn. In full-term infants, hyperbilirubinemia symptoms include severe jaundice, lethargy, and poorfeeding. Features of kernicterus may include choreoathetoid cerebral palsy, mental retardation, sensorineural hearing loss, and gaze paresis. Kernicterus is not a reportable condition in the United States, and its prevalence is unknown; however, a pilot registry at a Pennsylvania hospital documented 90 cases in 21 states from 1984 to June 2001 (L. Johnson, Pennsylvania Hospital, Philadelphia, personal communication, 2001). This report summarizes case histories of four full-term, healthy infants who developed kernicterus and underscores that to prevent kernicterus, newborns must be screened and promptly treated for hyperbilirubinemia.

Entities:  

Mesh:

Year:  2001        PMID: 11428729

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  10 in total

Review 1.  Kernicterus as a 'Never-Event': a newborn safety standard?

Authors:  Vinod K Bhutani
Journal:  Indian J Pediatr       Date:  2005-01       Impact factor: 1.967

2.  Estimation of bilirubin using BiliChektrade mark, a transcutaneous bilirubin measurement device: Effects of gestational age and use of phototherapy.

Authors:  Ka Jangaard; H Curtis; Rb Goldbloom
Journal:  Paediatr Child Health       Date:  2006-02       Impact factor: 2.253

3.  Transcutaneous bilirubin measurement at the time of hospital discharge in a multiethnic newborn population.

Authors:  Douglas M Campbell; Karoon C Danayan; Valleverdina McGovern; Sohail Cheema; Brenda Stade; Michael Sgro
Journal:  Paediatr Child Health       Date:  2011-03       Impact factor: 2.253

4.  Cost-effectiveness analysis of a system-based approach for managing neonatal jaundice and preventing kernicterus in Ontario.

Authors:  Bin Xie; Orlando da Silva; Greg Zaric
Journal:  Paediatr Child Health       Date:  2012-01       Impact factor: 2.253

5.  Risk factors for hyperbilirubinemia in breastfed term neonates.

Authors:  Ying-Juang Chen; Wei-Chuan Chen; Chung-Ming Chen
Journal:  Eur J Pediatr       Date:  2011-06-17       Impact factor: 3.183

6.  Auditory neuropathy spectrum disorder in late preterm and term infants with severe jaundice.

Authors:  Satish Saluja; Asha Agarwal; Neelam Kler; Sanjiv Amin
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2010-09-15       Impact factor: 1.675

7.  Auditory toxicity in late preterm and term neonates with severe jaundice.

Authors:  Sanjiv B Amin; Satish Saluja; Arvind Saili; Nirupama Laroia; Mark Orlando; Hongyue Wang; Asha Agarwal
Journal:  Dev Med Child Neurol       Date:  2016-10-08       Impact factor: 5.449

8.  Induction of bilirubin clearance by the constitutive androstane receptor (CAR).

Authors:  Wendong Huang; Jun Zhang; Steven S Chua; Mohammed Qatanani; Yunqing Han; Riccarda Granata; David D Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

9.  Unbound Bilirubin and Auditory Neuropathy Spectrum Disorder in Late Preterm and Term Infants with Severe Jaundice.

Authors:  Sanjiv B Amin; Hongyue Wang; Nirupama Laroia; Mark Orlando
Journal:  J Pediatr       Date:  2016-03-04       Impact factor: 4.406

10.  Intravenous Immunoglobulin Use in Hemolytic Disease Due to ABO Incompatibility to Prevent Exchange Transfusion.

Authors:  Emel Okulu; Omer Erdeve; Ilknur Kilic; Ozgur Olukman; Sebnem Calkavur; Gokhan Buyukkale; Merih Cetinkaya; Dilek Ulubas; Nihal Demirel; Deniz Hanta; Sabahattin Ertugrul; Nazli Dilay Gultekin; Oguz Tuncer; Nihat Demir; Leyla Bilgin; Nejat Narli; Duran Yildiz; Demet Terek; Ozge Altun Koroglu; Canan Seren; Elif Ozyazici; Ramazan Ozdemir; Hatice Turgut; Fatma Narter; Yasemin Akin; Ahmet Ozyazici; Aysegul Zenciroglu; Huseyin Selim Asker; Zeynel Gokmen; Musa Salihli; Ali Bulbul; Umut Zubarioglu; Begum Atasay; Esin Koc
Journal:  Front Pediatr       Date:  2022-04-28       Impact factor: 3.418

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.